Your Molecule
Your Molecule
Antibody-Drug Conjugates (ADCs)
Antibody-Drug Conjugates (ADCs)
Formulation solutions for one of the most complex biologic modalities.
Tailored ADC formulations — from liquid to lyophilized, with handling capabilities up to Occupational Exposure Band (OEB) 5.
Early risk identification to design stable, patient-ready drug products
Why ADCs require special attention
Why ADCs require special attention
ADCs combine the targeting ability of antibodies with the therapeutic power of cytotoxic agents, offering highly specific treatments for oncology and other indications. Their complexity poses unique formulation challenges:
● Maintaining antibody stability while preserving payload potency.
● Preventing premature payload release during storage and administration.
● Ensuring safe handling in development and manufacturing (up to OEB 5).
● Balancing stability, efficacy, and usability for the final drug product.
Explore our full modalities hub
ADCs combine the targeting ability of antibodies with the therapeutic power of cytotoxic agents, offering highly specific treatments for oncology and other indications. Their complexity poses unique formulation challenges:
● Maintaining antibody stability while preserving payload potency.
● Preventing premature payload release during storage and administration.
● Ensuring safe handling in development and manufacturing (up to OEB 5).
● Balancing stability, efficacy, and usability for the final drug product.
Explore our full modalities hub
Our expertise
Our expertise
We bring extensive experience in stabilizing conjugated biologics across a wide range of payload classes and linker technologies. Our team develops both liquid and lyophilized formulations tailored to your ADC’s specific characteristics. We integrate:
● Molecular Modeling of protein, and drug conjugated protein to evaluate change of characteristics
● Orthogonal analytical characterization (antibody, linker, payload).
● Stability profiling across stress conditions.
● Excipient design to minimize degradation and aggregation.
● Robust formulation pathways aligned with target product profile.
We bring extensive experience in stabilizing conjugated biologics across a wide range of payload classes and linker technologies. Our team develops both liquid and lyophilized formulations tailored to your ADC’s specific characteristics. We integrate:
● Molecular Modeling of protein, and drug conjugated protein to evaluate change of characteristics
● Orthogonal analytical characterization (antibody, linker, payload).
● Stability profiling across stress conditions.
● Excipient design to minimize degradation and aggregation.
● Robust formulation pathways aligned with target product profile.
Ready to talk about your bispecific formulation strategy?
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Key Focus Areas
-
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
How we support you
1. Feasibility assessment: Molecular modeling and molecule characterization, risk identification, and early excipient strategy.
2. Formulation optimization: iterative DoE for stability, potency preservation, and manufacturability.
3. Stability programs: ICH-aligned long-term and accelerated studies.
4. Handling and scale-up: safe OEB 5 processes and Fill&Finish ready formulation packages.